Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer EntitiesWolfgang P. Fendler, Rainer Hamacher, Kim M. Pabst et al.|Clinical Cancer Research|2022Cited by 145
Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor EntitiesNader Hirmas, Wolfgang P. Fendler, Hans‐Ulrich Schildhaus et al.|Journal of Nuclear Medicine|2022Cited by 68
Superior Tumor Detection for<sup>68</sup>Ga-FAPI-46 Versus<sup>18</sup>F-FDG PET/CT and Conventional CT in Patients with CholangiocarcinomaKim M. Pabst, Wolfgang P. Fendler, Marija Trajkovic‐Arsic et al.|Journal of Nuclear Medicine|2023Cited by 63
Intraoperative <sup>68</sup>Ga-PSMA Cerenkov Luminescence Imaging for Surgical Margins in Radical Prostatectomy: A Feasibility StudyChristopher Darr, Boris Hadaschik, Nina N. Harke et al.|Journal of Nuclear Medicine|2020Cited by 43
Safety and Survival Outcomes of<sup>177</sup>Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior<sup>223</sup>Ra treatment: The RALU StudyKambiz Rahbar, Oliver Sartor, Markus Essler et al.|Journal of Nuclear Medicine|2022Cited by 37